Close Menu

NEW YORK (GenomeWeb) – HalioDx today announced its inception following a buyout by Qiagen Marseille's former executive management team. 

The company will focus on the immuno-oncology diagnostics space and develop assays for predicting patient response to several immuno-oncology solid tumor treatments.  

Along with Qiagen Marseille's managers, all of its 75 employees have transferred to HalioDx, a spokesperson for HalioDx told GenomeWeb. The firm's CEO is Vincent Fert.  

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Nature News reports that researchers in Japan hope to soon test the use of reprogrammed stem cells to treat damaged corneas.

A new approach may help limit the number of fish that are mislabeled at markets or restaurants, according to New Scientist.

At Slate, the R Street Institute's Nila Bala discusses the privacy rights of suspects that genetic genealogy approaches in law enforcement bring up.

In PNAS this week: numerous mobile genetic elements contribute to Vibrio cholerae drug resistance, troponin I mutations in sudden infant deaths, and more.